Which has stronger earnings and valuation, AVBP or RCKT?

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ArriVent BioPharma N/A N/A -$166.31M -$3.62 N/A Rocket Pharmaceuticals N/A N/A -$223.12M -$0.17 N/A

Is AVBP or RCKT more profitable?

ArriVent BioPharma's return on equity of -50.26% beat Rocket Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets ArriVent BioPharma N/A -50.26% -46.66% Rocket Pharmaceuticals N/A -52.77% -44.92%

Does the media favor AVBP or RCKT?

In the previous week, ArriVent BioPharma and ArriVent BioPharma both had 4 articles in the media. ArriVent BioPharma's average media sentiment score of 1.08 beat Rocket Pharmaceuticals' score of 0.46 indicating that ArriVent BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rocket Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor RARE or RCKT?

In the previous week, Ultragenyx Pharmaceutical had 33 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 37 mentions for Ultragenyx Pharmaceutical and 4 mentions for Rocket Pharmaceuticals. Ultragenyx Pharmaceutical's average media sentiment score of 0.70 beat Rocket Pharmaceuticals' score of 0.46 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 12 Very Positive mention(s) 7 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Rocket Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ABSI or RCKT?

In the previous week, Absci had 1 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 5 mentions for Absci and 4 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 0.46 beat Absci's score of 0.00 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Absci 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rocket Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MAZE or RCKT more profitable?

Maze Therapeutics' return on equity of -34.94% beat Rocket Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Maze Therapeutics N/A -34.94% -30.18% Rocket Pharmaceuticals N/A -52.77% -44.92%

Does the media prefer MAZE or RCKT?

In the previous week, Maze Therapeutics had 4 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 8 mentions for Maze Therapeutics and 4 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 0.46 beat Maze Therapeutics' score of 0.36 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Rocket Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, RCKT or CGEM?

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rocket Pharmaceuticals N/A N/A -$223.12M -$0.17 N/A Cullinan Therapeutics N/A N/A -$219.88M -$3.10 N/A

Is RCKT or CGEM more profitable?

Rocket Pharmaceuticals' return on equity of -52.77% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rocket Pharmaceuticals N/A -52.77% -44.92% Cullinan Therapeutics N/A -52.89% -48.18%

Does the media prefer RCKT or CGEM?

In the previous week, Rocket Pharmaceuticals had 1 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 4 mentions for Rocket Pharmaceuticals and 3 mentions for Cullinan Therapeutics. Cullinan Therapeutics' average media sentiment score of 0.70 beat Rocket Pharmaceuticals' score of 0.46 indicating that Cullinan Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cullinan Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Rocket Pharmaceuticals (RCKT) Competitors

$3.02 -0.33 (-9.85%)

Closing price 04:00 PM Eastern

Extended Trading

$3.05 +0.03 (+0.99%)

As of 07:53 PM Eastern

Compare

RCKT vs. AVBP, RARE, ABSI, MAZE, and CGEM

Should you buy Rocket Pharmaceuticals stock or one of its competitors? Rocket Pharmaceuticals's main competitors and comparable companies include ArriVent BioPharma (AVBP), Ultragenyx Pharmaceutical (RARE), Absci (ABSI), Maze Therapeutics (MAZE), and Cullinan Therapeutics (CGEM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Rocket Pharmaceuticals compare to ArriVent BioPharma?

ArriVent BioPharma (NASDAQ:AVBP) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 8.6% of ArriVent BioPharma shares are held by insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

ArriVent BioPharma presently has a consensus target price of $44.86, suggesting a potential upside of 48.04%. Rocket Pharmaceuticals has a consensus target price of $8.63, suggesting a potential upside of 185.60%. Given Rocket Pharmaceuticals' higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.36

ArriVent BioPharma has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market.

ArriVent BioPharma's return on equity of -50.26% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-50.26%	-46.66%
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%

In the previous week, ArriVent BioPharma and ArriVent BioPharma both had 4 articles in the media. ArriVent BioPharma's average media sentiment score of 1.08 beat Rocket Pharmaceuticals' score of 0.46 indicating that ArriVent BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rocket Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A

Summary

ArriVent BioPharma beats Rocket Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

Rocket Pharmaceuticals has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -81.79%. Rocket Pharmaceuticals' return on equity of -52.77% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-44.40%
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Ultragenyx Pharmaceutical has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

Rocket Pharmaceuticals has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	2.18	-$575M	-$5.84	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A

In the previous week, Ultragenyx Pharmaceutical had 33 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 37 mentions for Ultragenyx Pharmaceutical and 4 mentions for Rocket Pharmaceuticals. Ultragenyx Pharmaceutical's average media sentiment score of 0.70 beat Rocket Pharmaceuticals' score of 0.46 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	12 Very Positive mention(s)	7 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Rocket Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ultragenyx Pharmaceutical currently has a consensus price target of $34.58, indicating a potential upside of 132.39%. Rocket Pharmaceuticals has a consensus price target of $8.63, indicating a potential upside of 185.60%. Given Rocket Pharmaceuticals' higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Ultragenyx Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.48
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.36

Summary

Rocket Pharmaceuticals beats Ultragenyx Pharmaceutical on 8 of the 15 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Absci?

Absci (NASDAQ:ABSI) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

52.1% of Absci shares are owned by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 10.5% of Absci shares are owned by insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Rocket Pharmaceuticals has a net margin of 0.00% compared to Absci's net margin of -7,756.38%. Rocket Pharmaceuticals' return on equity of -52.77% beat Absci's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Absci	-7,756.38%	-61.71%	-54.52%
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%

In the previous week, Absci had 1 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 5 mentions for Absci and 4 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 0.46 beat Absci's score of 0.00 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Absci	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rocket Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Absci has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Absci	$2.80M	596.96	-$115.18M	-$0.80	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A

Absci currently has a consensus price target of $13.71, indicating a potential upside of 40.80%. Rocket Pharmaceuticals has a consensus price target of $8.63, indicating a potential upside of 185.60%. Given Rocket Pharmaceuticals' higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Absci.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Absci	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.36

Absci has a beta of 2.42, suggesting that its stock price is 142% more volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

Summary

Rocket Pharmaceuticals beats Absci on 9 of the 15 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Maze Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

Maze Therapeutics presently has a consensus price target of $63.40, indicating a potential upside of 125.70%. Rocket Pharmaceuticals has a consensus price target of $8.63, indicating a potential upside of 185.60%. Given Rocket Pharmaceuticals' higher possible upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than Maze Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.08
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.36

Maze Therapeutics' return on equity of -34.94% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-34.94%	-30.18%
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%

In the previous week, Maze Therapeutics had 4 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 8 mentions for Maze Therapeutics and 4 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 0.46 beat Maze Therapeutics' score of 0.36 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Rocket Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 5.3% of Maze Therapeutics shares are held by insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Maze Therapeutics has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	9.32	-$131.12M	-$2.52	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A

Maze Therapeutics has a beta of 2.17, meaning that its share price is 117% more volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market.

Summary

Maze Therapeutics beats Rocket Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Cullinan Therapeutics?

Rocket Pharmaceuticals (NASDAQ:RCKT) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

In the previous week, Rocket Pharmaceuticals had 1 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 4 mentions for Rocket Pharmaceuticals and 3 mentions for Cullinan Therapeutics. Cullinan Therapeutics' average media sentiment score of 0.70 beat Rocket Pharmaceuticals' score of 0.46 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rocket Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cullinan Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.4% of Rocket Pharmaceuticals shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 21.3% of Rocket Pharmaceuticals shares are held by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A

Rocket Pharmaceuticals has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of 0.02, indicating that its share price is 98% less volatile than the broader market.

Rocket Pharmaceuticals presently has a consensus price target of $8.63, indicating a potential upside of 185.60%. Cullinan Therapeutics has a consensus price target of $33.00, indicating a potential upside of 95.61%. Given Rocket Pharmaceuticals' higher probable upside, equities analysts plainly believe Rocket Pharmaceuticals is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.36
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Rocket Pharmaceuticals' return on equity of -52.77% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%
Cullinan Therapeutics	N/A	-52.89%	-48.18%

Summary

Rocket Pharmaceuticals beats Cullinan Therapeutics on 8 of the 12 factors compared between the two stocks.

Get Rocket Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RCKT vs. The Competition

Export

Metric	Rocket Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$367.74M	$3.90B	$7.21B	$13.10B
Dividend Yield	N/A	3.64%	2.53%	13.00%
P/E Ratio	-17.76	13.95	274.58	25.69
Price / Sales	N/A	1,357.85	639.38	80.65
Price / Cash	N/A	109.50	76.31	52.02
Price / Book	1.18	15.30	10.44	6.32
Net Income	-$223.12M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-13.22%	-0.22%	0.51%	1.35%
1 Month Performance	-13.96%	-6.06%	-3.38%	-3.68%
1 Year Performance	-2.58%	34.37%	16.04%	5.56%

Rocket Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RCKT Rocket Pharmaceuticals	2.5649 of 5 stars	$3.02 -9.9%	$8.63 +185.6%	+5.3%	$367.74M	N/A	N/A	202
AVBP ArriVent BioPharma	2.5672 of 5 stars	$28.57 -1.5%	$44.86 +57.0%	+62.8%	$1.43B	N/A	N/A	77	Positive News Analyst Forecast
RARE Ultragenyx Pharmaceutical	3.4079 of 5 stars	$13.61 -4.8%	$36.63 +169.2%	-47.0%	$1.41B	$673M	N/A	1,371	Analyst Forecast
ABSI Absci	2.3111 of 5 stars	$8.09 -1.5%	$13.71 +69.5%	+298.1%	$1.41B	$2.80M	N/A	140	News Coverage Analyst Forecast
MAZE Maze Therapeutics	2.8451 of 5 stars	$24.67 +0.3%	$66.00 +167.5%	+19.9%	$1.37B	$20M	N/A	141	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RCKT) was last updated on 9/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rocket Pharmaceuticals (RCKT) Competitors

RCKT vs. AVBP, RARE, ABSI, MAZE, and CGEM

How does Rocket Pharmaceuticals compare to ArriVent BioPharma?

Summary

How does Rocket Pharmaceuticals compare to Ultragenyx Pharmaceutical?

Summary

How does Rocket Pharmaceuticals compare to Absci?

Summary

How does Rocket Pharmaceuticals compare to Maze Therapeutics?

Summary

How does Rocket Pharmaceuticals compare to Cullinan Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT vs. The Competition

Rocket Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rocket Pharmaceuticals (RCKT) Competitors

RCKT vs. AVBP, RARE, ABSI, MAZE, and CGEM

How does Rocket Pharmaceuticals compare to ArriVent BioPharma?

Do insiders and institutionals hold more shares of AVBP or RCKT?

Do analysts prefer AVBP or RCKT?

Which has more risk and volatility, AVBP or RCKT?

Is AVBP or RCKT more profitable?

Does the media favor AVBP or RCKT?

Which has stronger earnings and valuation, AVBP or RCKT?

Summary

How does Rocket Pharmaceuticals compare to Ultragenyx Pharmaceutical?

Is RARE or RCKT more profitable?

Do insiders and institutionals believe in RARE or RCKT?

Which has more risk & volatility, RARE or RCKT?

Which has higher earnings & valuation, RARE or RCKT?

Does the media favor RARE or RCKT?

Do analysts recommend RARE or RCKT?

Summary

How does Rocket Pharmaceuticals compare to Absci?

Do institutionals and insiders have more ownership in ABSI or RCKT?

Is ABSI or RCKT more profitable?

Does the media prefer ABSI or RCKT?

Which has preferable earnings and valuation, ABSI or RCKT?

Do analysts rate ABSI or RCKT?

Which has more risk & volatility, ABSI or RCKT?

Summary

How does Rocket Pharmaceuticals compare to Maze Therapeutics?

Do analysts prefer MAZE or RCKT?

Is MAZE or RCKT more profitable?

Does the media prefer MAZE or RCKT?

Do insiders & institutionals have more ownership in MAZE or RCKT?

Which has stronger earnings and valuation, MAZE or RCKT?

Which has more volatility & risk, MAZE or RCKT?

Summary

How does Rocket Pharmaceuticals compare to Cullinan Therapeutics?

Does the media prefer RCKT or CGEM?

Do insiders & institutionals have more ownership in RCKT or CGEM?

Which has higher earnings and valuation, RCKT or CGEM?

Which has more risk and volatility, RCKT or CGEM?

Do analysts recommend RCKT or CGEM?

Is RCKT or CGEM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT vs. The Competition

Rocket Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools